The influence of exendin and GLP-1 on VCAM-1 and ICAM-1 production in endothelium stimulated by TNF-α and glycated albumin

Krzysztof Siemianowicz, Tomasz Francuz, Wojciech Garczorz

Department of Biochemistry, Medical University of Silesia, Katowice, Poland.

DOI: 10.4236/health.2012.412A225                

Abstract

A growing body of evidence indicates that incretins may have pleiotropic beneficial effects beyond lowering glucose blood concentration. The effect of GLP-1 and exendin-4 on coronary arteries endothelium in diabetic and obese individuals has been studied widely. TNF-a is one of adipocytokines. The aim of our study was to evaluate the influence of glycated albumin (GlyAlb; 100; 500 and 1000 mg/L) and proinflammatory cytokine, TNF-α (2.5 and 10 ng/mL), on expression of ICAM-1 and VCAM-1 in cultured human endothelial cells derived from coronary arteries. The next goal of the study was to evaluate the influence of GLP-1 (10 nM and 100 nM) and its analogue, exendin-4 (1 nM and 10 nM), on the expression of ICAM-1 and VCAM-1 in these cell line. TNF-a statistically significantly increased VCAM-1 production by endothelial cells, whereas GlyAlb statistically significantly augmented the expression of both tested adhesion mole- cules. Exendin-4 and GLP-1 statistically significantly reduced the expression of VCAM-1 in endothelial cells stimulated by GlyAlb in dose-de- pendent manner. When TNF-a was used as the stimulant only exendin-4 in the concentration of 10 nM statistically significantly reduced the expression of VCAM-1. Studied incretins in their both concentrations statistically significantly reduced the expression of ICAM-1 in endothelial cells stimulated by GlyAlb. The influence of TNF- a on the expression of ICAM-1 was statistically significantly reduced by both concentrations of exendin-4 but only by the higher concentration of GLP-1. The results of our present study indicate that incretins may present a group of agents developing pleiotropic effects beyond the reduction of blood glucose concentration. Their vaso-protective and cardioprotective action may be of importance in diabetic and obese individuals.

Keywords

Incretins; Endothelium; Adhesion Molecules

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	James, P.T., Rigby, N., Leach, R. and International Obe- sity Task Force (2004) The obesity epidemic, metabolic syndrome and future prevention strategies. European Journal of Cardi-ovascular Prevention and Rehabilitation, 11, 3-8. doi:10.1097/01.hjr.0000114707.27531.48
[2]	Koce?ak, P., Chudek, J. and Olszanecka-Glinianowicz, M. (2012) Prevalence of metabolic syndrome and insulin re- sistance in overweight and obese women according to the different diagnostic criteria. Minerva Endocrinologica, 37, 247-254.
[3]	Pichi, A., Gao, X., Belmadani, S., Potter, B.J., Focardi M., Chilian, W.M. and Zhang, C. (2006) Tumor necrosis fac- tor-a induces endothelial dysfunction in the prediabetic metabolic syndrome. Circulation Research, 99, 69-77. doi:10.1161/01.RES.0000229685.37402.80
[4]	Vykoukal, D. and Davies, M.G. (2011) Vascular biology of metabolic syn-drome. Journal of Vascular Biology, 54, 819-831. doi:10.1016/j.jvs.2011.01.003
[5]	Yudkin, J.S. (2007) In-flammation, obesity, and the meta- bolic syndrome. Hormone and Metabolic Research, 39, 707-709. doi:10.1055/s-2007-985898
[6]	Thorpe, S.R. and Baynes, J.W. (1996) Role of Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging, 9, 69-77. doi:10.2165/00002512-199609020-00001
[7]	Brubaker, P.L. (2007) Incretin-based therapies: Mimetics versus protease inhi-bitors. Trends in Endocrinology and Metabolism, 18, 240-245. doi:10.1016/j.tem.2007.06.005
[8]	Lovshin, J.A. and Drucker, D.J. (2009) Incretin-based therapies for type 2 diabetes mellitus. Nature Reviews Endocrinology, 5, 262-269. doi:10.1038/nrendo.2009.48
[9]	Ban, K., Noyan-Ashraf, M.H., Hoefer, J., Bolz, S.S., Drucker, D.J. and Husain, M. (2008) Cardioprotective and vasodilatory actions of gluca-gon-like peptide 1 recep- tor are mediated through both gluca-gon-like peptide 1 re- ceptor-dependent and -independent pathways. Circulation, 117, 2340-2350. doi:10.1161/CIRCULATIONAHA.107.739938
[10]	Ishibashi, Y., Matsui, T., Takeuchi, M. and Yamagishi, S. (2010) Gluca-gon-like peptide-1 (GLP-1) inhibits advan- ced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by sup- pressing AGE receptor (RAGE) expression. Biochemical and Biophysical Research Communications, 391, 1405- 1408. doi:10.1016/j.bbrc.2009.12.075
[11]	MacIsaac, R.J. and Jerums G. (2011) Intensive glucose control and cardiovascular outcomes in type 2 diabetes (April 2010). Heart, Lung and Circulation, 20, 647-654. doi:10.1016/j.hlc.2010.07.013
[12]	Ban, K., Kim, K.-H., Cho, C.-K., Sauvé, M., Diamandis, E.P., Backx, P.H., Drucker, D.J. and Husain, M. (2010) Glucagon-like peptide (GLP)-1 (9-36) amide-mediated cy- toprotection is blocked by exendin (9-39) yet does not require the known GLP-1 receptor. Endocrinology, 151, 1520-1531. doi:10.1210/en.2009-1197
[13]	Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R. and Watada, H. (2010) Inhibition of monocyte adhesion to endothelial cells and attenuation of atheroclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendine-4. Diabetes, 59, 1030-1037. doi:10.2337/db09-1694
[14]	Nathanson, D., Erdogdu, ?., Pernow, J., Zhang, Q. and Nystr?m, T. (2009) Endothelial dys-function induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regulatory Peptides, 157, 8-13. doi:10.1016/j.regpep.2009.07.003
[15]	Green, B.D., Hand, K.V., Dougan, J.E., McDonnell, B.M., Cassidy, R.S. and Grieve, D.J. (2008) GLP-1 and related peptides cause concentra-tion-dependent relaxation of rat aorta through a pathway in-volving KATP and cAMP. Ar- chives of Biochemistry and Bio-physics, 478, 136-142. doi:10.1016/j.abb.2008.08.001
[16]	Kelly, A.S., Bergenstal, R.M., Gonzales-Campy, J.M., Katz, H. and Bank, A.J. (2012) Effects of exenatide vs metformin on endothelial function in obese patients with pre-diabetes: A randomized trial. Cardi-ovascular Diabetology, 11, 64. http://www.cardiodiab.com/content/11/1/64
[17]	Liu, H., Hu, Y., Simpson, R.W. and Dear, A.E. (2008) Glucagon-like peptide-1 attenuates tumor necrosis factor- a-mediated induction of plasmogen activator inhibitor-1 expression. Journal of En-docrinology, 196, 57-65. doi:10.1677/JOE-07-0387
[18]	Basu, A., Charkoudian, N., Schrage, W., Rizza, R.A., Basu, R. and Joyner M.J. (2007) Beneficial effects of GLP-1 on endothelial function in humans: Dampening by glyburide but not by glimeperide. American Journal of Physiology—Endocrinology and Metabolism, 293, E1289- E1295. doi:10.1152/ajpendo.00373.2007
[19]	Gaspari, T., Liu, H.B., Welungoda, I., Hu, Y., Widdop, R.E., Knudsen, L., Simpson, R.W. and Dear, A.E. (2011) A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expres- sion in an ApoE-/- mouse model. Diabetes & Vascular Disease Research, 8, 117-124. doi:10.1177/1479164111404257
[20]	Dozier, K.C., Cureton, E.L., Kwan, R.O., Curran, B., Sadjadi, J. and Victorino, G.P. (2009) Glucagon-like pep- tide-1 protects mesenteric endothe-lium from injury during inflammation. Peptides, 30, 1735-1741. doi:10.1016/j.peptides.2009.06.019
[21]	Kodera, R., Shikata, K., Kataoka, H.U., Takatsuka, T, Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., Sato, C., Ogawa, D. and Makino H. (2011) Glucagon-like peptide-1 receptor agonist amelio- rates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia, 54, 965-978. doi:10.1007/s00125-010-2028-x
[22]	Siemianowicz, K., Francuz, T., Gminski, J., Telega, A. and Syzdól, M. (2005) Endothelium dysfunction markers in patients with diabetic retinopathy. International Jour- nal of Molecular Medicine, 15, 459-462.